Bryan Garnier - PHARMACEUTICALS IO-based combinations have moved to SoC in 1L RCC

Report

Bryan Garnier

Eric Le Berrigaud

PHARMACEUTICALS IO-based combinations have moved to SoC in 1L RCC

IO-based combinations have moved to SoC in 1L RCC

23/10/2018 2 EN

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Le Berrigaud

Other Reports from Bryan Garnier

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Alfen: H1 2025 results, mid-term outlook lowered

Alfen published H1 2025 figures yesterday. Revenue came in at EUR211.5m (-13.9% YoY vs. EUR245.7m in H1 2024) mainly with challenging dynamics in EV charging and Energy Storage, while benefiting from favourable base effects in Smart Grids, which was impacted by moistening issues in Q2 2024. This wa

1h / 16m 1h / 16m 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Egetis Q2: initial Germany launch, key catalysts still ahead

Egetis has reported Q2 results, marking the first commercial sales of Emcitate in Germany following its 1st May launch, and a cash position of SEK203m, providing an est. runway into Q1 2026. While exact German sales figures remain undisclosed, SEK14.5m in total revenues (vs SEK13.9m in Q2 2024) inc

1h / 28m 1h / 28m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Cinclus Pharma: Q2 driven by BD progress, Phase 3 trial nearing initiation

Cinclus’ Q2 update focused on balance sheet items and a recap of corporate achievements. The company reported a cash position of SEK589m and operating expenses of SEK80.9m, up from the prior quarter - consistent with expectations given the Phase 3 trial ramp-up. With support from the Zentiva partne

August 20, 2025 August 20, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

PHARMACEUTICALS IO-based combinations have moved to SoC in 1L RCC

Alfen: H1 2025 results, mid-term outlook lowered

Egetis Q2: initial Germany launch, key catalysts still ahead

Cinclus Pharma: Q2 driven by BD progress, Phase 3 trial nearing initiation

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe